Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02235'
s ROE % Range Over the Past 10 Years
Min: -36.26 Med: -3.26 Max: 2.05
Current: 2.05
During the past 7 years, MicroTech Medical (Hangzhou) Co's highest ROE % was 2.05%. The lowest was -36.26%. And the median was -3.26%.
HKSE:02235's ROE % is ranked worse than 52.13% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.76
vs HKSE:02235: 2.05
MicroTech Medical (Hangzhou) Co (HKSE:02235) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
MicroTech Medical (Hangzhou) Co ROE % Related Terms
MicroTech Medical (Hangzhou) Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MicroTech Medical (Hangzhou) Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroTech Medical (Hangzhou) Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroTech Medical (Hangzhou) Co's ROE % distribution charts can be found below:
* The bar in red indicates where MicroTech Medical (Hangzhou) Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
MicroTech Medical (Hangzhou) Co (HKSE:02235) has a ROE % of 4.28% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MicroTech Medical (Hangzhou) Co and its competitors. According to the industry distribution chart, MicroTech Medical (Hangzhou) Co ranks #416 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 52.1%.
Is MicroTech Medical (Hangzhou) Co's ROE % too high?
MicroTech Medical (Hangzhou) Co's current ROE % is 4.28%. The Medical Devices & Instruments industry median ROE % is 2.76. MicroTech Medical (Hangzhou) Co's value of 4.28% is 55.1% above this industry median. Based on the distribution chart, MicroTech Medical (Hangzhou) Co ranks #416 out of 798 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MicroTech Medical (Hangzhou) Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroTech Medical (Hangzhou) Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroTech Medical (Hangzhou) Co ranks #416 out of 798 companies for ROE %. This places MicroTech Medical (Hangzhou) Co in the lower half of its industry. The industry median ROE % is 2.76. MicroTech Medical (Hangzhou) Co's value of 4.28% is 55.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.76, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroTech Medical (Hangzhou) Co's current ROE % of 4.28% is 55.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MicroTech Medical (Hangzhou) Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroTech Medical (Hangzhou) Co's current ROE % is 4.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroTech Medical (Hangzhou) Co stock overvalued right now?
Based on GuruFocus' analysis, MicroTech Medical (Hangzhou) Co (HKSE:02235) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.94, compared to a current price of HK$7.26 — trading 54.5% below its estimated fair value. The current ROE % is 4.28% and 55.1% above the Medical Devices & Instruments industry median of 2.76. MicroTech Medical (Hangzhou) Co's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MicroTech Medical (Hangzhou) Co (HKSE:02235), the current ROE % is 4.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroTech Medical (Hangzhou) Co (HKSE:02235) Overvalued in 2026?
Based on GuruFocus' analysis, MicroTech Medical (Hangzhou) Co stock appears to be undervalued.
The current stock price of HK$7.26 is trading 54.5% below its estimated GF Value™ of HK$15.94.
GuruFocus considers MicroTech Medical (Hangzhou) Co to be Possible Value Trap.
Key valuation signals for HKSE:02235:
ROE %: 4.28%
GF Value™: HK$15.94 vs. price of HK$7.26 (54.5% below fair value)
Industry Position: 55.1% above the Medical Devices & Instruments median (#416 of 798)
No single metric tells the full story. See the HKSE:02235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroTech Medical (Hangzhou) Co Ltd is focused on diabetes management, providing both diabetes treatment and diabetes monitoring medical devices to improve the diabetes management in China and globally. The Group operates in a large and fast-growing diabetes monitoring, treatment and management market in China and globally with unmet clinical needs. The company derives a majority of its revenue from China.
80GF Score
Get the complete analysis for HKSE:02235
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02235 has been successfully added to your 
